Both represent important advances in obesity medicine, and the most appropriate option depends on an individual's medical history , treatment goals , and a discussion with their healthcare provider
Glucagon Receptor Engagement Energy Expenditure and Hepatic Metabolism Although GLP3 exhibits lower potency at glucagon receptors compared to native glucagon, this component of its triagonist mechanism appears critical for its metabolic effects[8]: Increased energy expenditure through thermogenic activation Enhanced hepatic fatty acid oxidation and reduced hepatic steatosis Modulation of hepatic glucose production during fasted states Promotion of lipolysis in adipose tissue Potential effects on lean mass preservation through metabolic adaptations In vitro studies demonstrated that GLP3 achieves efficacy similar to natural glucagon in stimulating glucose production in hepatocytes, while in adipocytes it surpasses native GIP in inducing lipolysis[9]
Triple-Hormone-Receptor Agonist Retatrutide for Obesity PubMed record
They mimic two key hormones: GLP-1 (glucagon-like peptide-1) This hormone helps keep blood sugar in check and curbs your appetite by slowing how quickly food moves through your stomach
This may help explain why protein is often considered one of the most satiating nutrients
Lower levels of lipids (except high-density lipoprotein, also called good cholesterol), which indicates a lower risk of heart disease and stroke
